1.
Int Forum Allergy Rhinol
; 2024 Jul 03.
Article
in English
| MEDLINE
| ID: mdl-38958596
ABSTRACT
KEY POINTS: A persistent type 2 endotype signature exists in recalcitrant chronic rhinosinusitis with nasal polyps mucosa on dupilumab. Revision sinus surgery immediately prior to dupilumab reduces long-term interleukin (IL)-4/IL-13 tissue mRNA. Pre-dupilumab revision surgery is associated with reduced tissue eosinophils and GATA-3+ cells.